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Abstract
Aims: To prospectively evaluate the relationship between left atrial volume (LAV) and the risk of clinical events in
patients with hypertrophic cardiomyopathy (HCM).
Methods: We enrolled a total of 141 HCM patients with sinus rhythm and normal pump function, and 102
patients (73 men; mean age, 61 ± 13 years) who met inclusion criteria were followed for 30.8 ± 10.0 months. The
patients were divided into two groups with or without major adverse cardiac and cerebrovascular events (MACCE),
a composite of stroke, sudden death, and congestive heart failure. Detailed clinical and echocardiographic data
were obtained.
Results: MACCE occurred in 24 patients (18 strokes, 4 congestive heart failure and 2 sudden deaths). Maximum
LAV, minimum LAV, and LAV index (LAVI) corrected for body surface area (BSA) were significantly greater in
patients with MACCE than those without MACCE (maximum LAV: 64.3 ± 25.0 vs. 51.9 ± 16.0 ml, p = 0.005;
minimum LAV: 33.9 ± 15.1 vs. 26.2 ± 10.9 ml, p = 0.008; LAVI: 40.1 ± 15.4 vs. 31.5 ± 8.7 ml/mm2, p = 0.0009), while
there were no differences in the other echocardiographic parameters.
LAV/BSA of ≥ 40.4 ml/m2 to identify patients with cardiovascular complications with a sensitivity of 73% and a
specificity of 88%.
Conclusion: LAVI may be an effective marker for detecting the risk of MACCE in patients with HCM and normal
pump function.
Keywords: hypertrophic cardiomyopathy, left atrial volume, cardiac and cerebrovascular events, paroxysmal atrial
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Introduction
Hypertrophic cardiomyopathy (HCM) is a complex pri-
mary and genetically transmitted cardiac disease with
diverse clinical courses that include a stable clinical
course, progressive congestive symptoms requiring ther-
apeutic intervention, and sudden cardiac death [1,2].
Paroxysmal atrial fibrillation (PAF) is a common compli-
cation of HCM [3-5], often leading to acute or progres-
sive heart failure and cerebral infarction. We previously
showed that left atrial volume (LAV) was significantly
greater in HCM patients with PAF than in those with-
out PAF, and that LAV could more accurately predict
the occurrence of PAF than could LA dimension [6].
Furthermore, it was recently shown that a dilated LA
volume at baseline, a rapid increase in LA volume, and
a New York Heart Association functional class were
independent predictors of unfavorable outcomes in
patients with HCM [7].
In the present study, we investigated the clinical sig-
nificance of echocardiographic LAV, as well as other
echocardiographic and clinical parameters, in HCM
patients with preserved normal pump function. Further-
more, HCM patients were assessed for major adverse
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cardiac and cerebrovascular events (MACCE), and the
relationship between LAV and MACCE was determined.
Methods
Study patients
We studied 141 consecutive patients diagnosed with
HCM by two-dimensional echocardiography at our
institution between January 2000 and February 2002.
Exclusion criteria were chronic AF, other arrhythmias,
prior stroke, permanent pacemaker implantation, and
poor imaging. In this study, we excluded the patients
with left ventricular (LV) outflow tract obstruction.
The final population consisted of 102 patients who met
inclusion criteria. Although patients with hypertension
were included in our study, the vast majority of hyperten-
sive subjects carried only mild or well-controlled hyper-
tension. All patients had normal pump function and were
in sinus rhythm at the time of examination.
Echocardiography
In each patient, the diagnosis of HCM was made on the
basis of a two-dimensional echocardiographic finding of
a hypertrophied and non-dilated LV (wall thickness ≧
15 mm), in the absence of any cardiac or systemic dis-
ease capable of producing a comparable magnitude of
LV hypertrophy. The greatest thickness measured at any
site in the LV wall was considered to represent the max-
imal wall thickness. All patients except apical hypertro-
phy had asymmetric septal hypertrophy and septum/
posterior wall thickness ratio of 1.3 or more. LAVs were
assessed off-line using the modified biplane area-length
method. LAV was determined at the time of mitral
valve opening (maximal volume) and mitral valve clo-
sure (minimal volume). The area of the left atrium was
determined by tracing the endocardial border of the left
atrium in apical four-chamber and apical long-axis
views. The length of the left atrium was measured from
the midline of the mitral annulus to the opposite wall.
Both the absolute volume (LAV) and the maximum
volume indexed to body surface area (BSA) (LAV/BSA)
were determined. LAV data were measured by an inde-
pendent observer blinded to the groups.
Other echocardiographic parameters were obtained
from the echocardiography reports. We retrieved LA dia-
meter, LV end-systolic and end-diastolic dimensions, LV
septal and posterior wall thickness, LV ejection fraction
(EF), peak mitral flow velocity of the early rapid filling
wave (E), peak velocity of the late filling wave due to atrial
contraction (A), the E/A ratio, and the deceleration time
of the early mitral filling wave (DcT). LA diameter was
measured in a parasternal long-axis view. LA diameter and
LV wall thickness were obtained according to the stan-
dards of the American Society of Echocardiography (ASE)
[8]. EF was calculated from apical two-and four-chamber
views according to the biplane modified Simpson rule.
The cut-off used for normality of EF was 60%.
The severity of mitral regurgitation (MR) was semi-
quantitatively evaluated by color Doppler echocardiogra-
phy in the apical four-chamber view. We measured MR
jet area and LA area and calculated the ratio of MR jet
area to LA area. They were graded as none, mild (ratio
jet area/LA area <20%), and moderate or severe (jet
area/LA area > 20%).
Identification of PAF
Clinical information was obtained from medical records.
All patients were followed up in our hospital. The pre-
sence of PAF was documented by either 12-lead resting
electrocardiogram (ECG) or 24 h ambulatory ECG. The
patients with PAF had at least one symptomatic episode.
The patients with sinus rhythm were free from chest
symptoms and documentation of PAF using the above cri-
teria. No patients were complicated with congestive heart
failure or other arrhythmias at the time of examination.
Follow-up data
We followed up the study patients for a follow-up of
30.8 ± 10.0 months (median, 31 months; longest obser-
vation, 80 months). The primary endpoints were major
adverse cardiac and cerebrovascular events (MACCE),
defined as hospitalization for worsening congestive heart
failure, a composite of stroke and sudden cardiac death.
Sudden cardiac death was defined as unexpected sudden
cardiac collapse within one hour of new symptoms or
nocturnal death with no antecedent history of worsening
of symptoms. MACCE data were obtained from charts
or by telephone interview with the patients.
Statistical analysis
All continuous variables are expressed as mean ± SD if
the values were parametrically distributed. Values were
compared between the groups by unpaired Student’s t
test as they were parametrically distributed. A p-value
<0.05 was considered statistically significant. Receiver
operating characteristics (ROC) curve analysis to deter-
mine the optimal cut-off values for the maximum LAV,
and LAV/BSA was used to distinguish HCM patients at
higher risk of MACCE. Survival curves were constructed
according to the Kaplan-Meier method. Multivariate
Cox regression analysis was performed to assess echo-
cardiographic parameters for MACCE. All statistical
analyses were performed using SPSS statistical software
(Version 11; SPSS Inc., Chicago, IL, United States).
Results
Baseline characteristics
Of the 141 consecutive patients eligible for the present
study, 102 patients (61 ± 13 years) were followed up for
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the occurrence of MACCE. The median follow-up per-
iod was 30.8 months (range, 12-80 months). MACCE
occurred in 24 patients (Group A), while the remaining
78 patients showed no signs of MACCE (Group B). The
baseline clinical characteristics of the study population
are summarized in Table 1. The prevalence of hyperten-
sion and PAF was significantly higher in Group A than
in Group B. There were no significant differences in any
other clinical and laboratory variables between the two
groups.
In Group A, during follow-up, there were 24 events of
MACCE: 18 strokes, 4 congestive heart failure and 2
sudden deaths (Table 2). In 18 patients presented with
stroke, the rhythm of 7 patients was atrial fibrillation at
the time of complications.
Morphologic classification of HCM
The study patients included 21 patients with apical
hypertrophy, seven patients with basal hypertrophy, four
patients with diffuse hypertrophy of the ventricular sep-
tum, 61 patients with diffuse hypertrophy of the ventri-
cular septum and the antero-lateral free wall, and nine
patients with hypertrophy of the lateral wall (Table 3).
LV function
All patients had normal pump function. LV end-diastolic
dimension, LV end-systolic dimension, interventricular
septal wall thickness, and EF were not significantly differ-
ent between Group A and Group B (Table 4). LV diasto-
lic functions are also shown in Table 4, and there were
no differences between the two groups.
Incidence and severity of MR
Only 10 patients had moderate or severe MR. In Group
A, four patients (17%) had moderate or severe MR. The
prevalence and the severity of MR were significantly
greater in Group A than in Group B (Table 4).
LA size
Although there were no significant differences in LA
diameter between the two groups maximum LAV,
minimum LAV, and LAV/BSA were significantly
greater in Group A than in Group B (Table 4). ROC
curve analysis revealed a maximum LAV of ≥ 62.7 ml
to identify patients with cardiovascular complications
with a sensitivity of 73% and a specificity of 82% (area
under ROC curve = 0.853). ROC curve analysis
revealed a LAV/BSA of ≥ 40.4 ml/m2 to identify
patients with cardiovascular complications with a sen-
sitivity of 73% and a specificity of 88% (area under
ROC curve = 0.864) (Figure 1).
The Kaplan-Meier analysis also showed poor out-
comes for MACCE in patients with LAV/BSA > 41 ml/
m2 (p = 0.001, Log-rank test) (Figure 2).
From our study, there were no patients with MACCE
in the group with a LAV/BSA < 41 ml/m2 after 33
months. By multivariate Cox regression analysis, LAV/
BSA was an independent predictor for MACCE (Table 5).
Table 1 Baseline clinical characteristics of the study
population
Total Group A Group B P-value
Age 61 ± 13 64 ± 12 59 ± 12 0.14
Male 73 (72%) 18 (74%) 55 (71%) 0.63
BPs (mmHg) 130 ± 19 137 ± 23 128 ± 17 0.04
BPd (mmHg) 77 ± 10 79 ± 10 76 ± 10 0.14
Height (m) 1.62 ± 0.09 1.60 ± 0.08 1.63 ± 0.09 0.12
Weight (kg) 61.8 ± 11.1 61.9 ± 9.6 61.7 ± 11.8 0.94
BSA (m2 ) 1.67 ± 0.18 1.65 ± 0.16 1.67 ± 0.19 0.75
History of
HT
43 (42%) 16 (67%) 27 (35%) <0.0001
DM 10 (10%) 3 (13%) 7 (9%) 0.37
HL 49 (48%) 12 (50%) 37 (47%) 0.67
PAF 23 (23%) 13 (54%) 10 (13%) <0.0001
Medications
Aspirin
15 (15%) 8 (33%) 7 (9%) <0.0001
Warfarin 4 (17%) 4 (17%) 0 <0.001
Calcium ant. 41 (40%) 11 (46%) 30 (38%) 0.25
Beta-blockers 44 (43%) 11 (46%) 33 (42%) 0.57
Diuretics 6 (6%) 3 (13%) 3 (4%) 0.02
ACE inhibitor 19 (19%) 8 (33%) 11 (14%) 0.002
BPs, systolic blood pressure; BPd, diastolic blood pressure
BSA, body surface area; PAF, paroxysmal atrial fibrillation
Table 2 Events of 24 patients with Hypertrophic
Cardiomyopathy
Events N = 24
stoke 18 (75%)
congestive heart failure 4 (17%)
sudden death 2 (8%)
Table 3 Morphologic classification of HCM
Total Group A Group B p-value
APH 21 (21%) 6 (25%) 15 (19%) 0.31
Type 1 7 (7%) 1 (4%) 6 (8%) 0.23
Type 2 4 (4%) 1 (4%) 3 (4%) 1.00
Type 3 61 (60%) 14 (59%) 47 (60%) 0.89
Type 4 9 (9%) 2 (8%) 7 (9%) 0.80
APH, apical hypertrophy
Type 1, basal septal hypertrophy
Type 2, diffuse hypertrophy of the ventricular septum
Type 3, diffuse hypertrophy of the ventricular septum and antero-lateral free
wall
Type 4, hypertrophy of the lateral wall
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Discussion
In the present study, LA volume assessed by echocardio-
graphy was strongly associated with future risk of
MACCE (a composite of stroke, sudden death, and con-
gestive heart failure) in HCM patients with normal
pump function. However, LA diameter, a standard mea-
sure used to assess LA size, was not associated with the
risk of MACCE. A previous study reported that HCM
patients have a 4-6-fold increased risk of developing AF
compared with the general population [5]. Furthermore,
once AF has developed the risk of ischemic stroke may
increase 8-fold in HCM patients relative to HCM
patients with sinus rhythm, presumably via an increase
in cardioembolic stroke [9]. In our study the risk of
stroke was comparable between patients with chronic
AF and PAF.
Outcome and LA volume
We previously reported that LA volume in sinus rhythm
may be a strong predictor of future AF in patients with
HCM [6]. Mild LA enlargement is common in HCM,
and may be a consequence of impaired diastolic func-
tion associated with the thickened and noncompliant
Table 4 Baseline echocardiographic characteristics of the
study population
Total Group A Group B p-value
LAD (cm) 3.81 ± 0.60 3.91 ± 0.56 3.80 ± 0.59 0.40
LAV, max (ml) 54.6 ± 19.2 64.3 ± 25.0 51.9 ± 16.0 0.005
LAV, min (ml) 27.9 ± 12.4 33.9 ± 15.1 26.2 ± 10.9 0.008
LAV/BSA (ml/m2) 34.0 ± 11.8 40.1 ± 15.4 31.5 ± 8.7 0.0009
LVD, diastole (cm) 4.34 ± 0.89 4.36 ± 0.51 4.33 ± 0.49 0.77
LVD, systole (cm) 2.59 ± 0.54 2.64 ± 0.50 2.57 ± 0.55 0.62
IVS (cm) 1.56 ± 0.43 1.59 ± 0.45 1.50 ± 0.40 0.37
EF (%) 66.8 ± 6.6 67.5 ± 6.2 66.5 ± 6.8 0.53
E/A 1.04 ± 0.4 1.2 ± 0.4 1.0 ± 0.4 0.42
DcT (msec) 244 ± 79 243 ± 71 254 ± 103 0.57
MR
None
15 (15%) 2 (8%) 13 (17%) 0.05
Mild 77 (76%) 18 (75%) 59 (76%) 0.87
Moderate or severe 10 (10%) 4 (17%) 6 (7%) 0.03
LAD, left atrial diameter; LAV, left atrial volume
BSA, body surface area; LVD, left ventricular dimension
IVS, intraventricular septum; EF, ejection fraction
E/A, ratio of early to late transmitral peak flow velocity
DcT, deceleration time; MR, mitral regurgitation
Figure 1 Receiver operating characteristics curve for determining the optimal cut-off value for identifying patients with cardiovascular
complications from maximum left atrial volume (LAV), minimum LAV and LAV corrected to body surface area (LAV/BSA); Sen.,
sensitivity; Spec., specificity.
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LV [10. 11]. Although assessment of LA enlargement
appears to provide important information about the
patients’ outcome, unidimensional M-mode LA diameter
cannot accurately measure LA size [12]. Similar to that
previously described, our series indicated that LA
volume was a better predictor of PAF and MACCE than
was superior LA diameter [6,13-15].
AF and stroke
LA dilatation promotes stasis of blood, which in turn
predisposes to thrombus formation and the potential for
embolization. In our study, LA size was associated with
important risk factors for stroke and death. These obser-
vations underline the benefits of defining clinical mar-
kers able to non-invasively identify those patients with
HCM who are at risk of developing PAF and suffering
complication.
There are several factors that may influence outcome
in patients with HCM and the occurrence of stroke and
LA enlargement.
Indeed, in this study, Group A had a significantly
greater number of patients with hypertension and PAF
both of which may predispose to stroke and heart
failure.
MR influences also in a relevant fashion LA volumes.
In our study, Group A had a significantly greater num-
ber of patients with severe MR.
Echocardiography and risk for sudden death assessment
Using two-dimensional echocardiographic measure-
ments, Spirito et al. showed that the risk of sudden
death increased progressively in direct relation to wall
thickness [3]. But, there were no significant differences
Figure 2 Kaplan-Meier curves for MACCE, with the log-rank test (p = 0.001).
Table 5 Predictors of MACCE by Cox regression
multivariable analysis
RR(95% CI) Significance
LAD (cm) 0.86 (0.22-3.36) 0.83
LAV, max (ml) 1.03 (0.95-1.11) 0.51
LAV, min (ml) 0.98 (0.90-1.06) 0.57
LAV/BSA (ml/m2) 0.88 (0.80-0.97) 0.009
LAD, left atrial diameter; LAV, left atrial volume
BSA, body surface area;
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of the distribution of hypertrophy between two groups
in our study.
Previous paper showed that LV outflow tract obstruc-
tion is associated with an increased risk of sudden death
[16]. Otherwise, Losi MA et al. showed that there was
no statistical differences between patients with and with-
out obstruction on outcome [7].
Clinically, HCM patients without obstruction were
sometimes occurred complications. There were some
clinical significances of echocardiographic parameters in
patients with nonobstructive hypertrophic
cardiomyopathy.
Study limitations
First, the method we used for detection of PAF based on
clinical documentation with electrocardiographic confir-
mation may have underestimated the actual incidence of
PAF. Some patients with AF may have been asympto-
matic, and if they did not present to the hospital then
the arrhythmia could have remained undetected. How-
ever, all patients presented at least once to our hospital
within a 1-year period. 7 of 18 patients were in AF at
the time they presented with a stroke. Second, we only
measured the LA volume at baseline, not during follow-
up. As the dilatation rate of LA volume may also be an
important prognostic factor in patients with HCM. And
in our study, we did not investigate the patients with LV
outflow obstruction. Previous paper showed that LV
outflow tract obstruction is associated with an increased
risk of sudden death [16]. In this study, we excluded the
patients with obstruction. We investigated whether LA
volume predict adverse cardiac and cerebrovascular
events in HCM patients, as exclusive for the influence
of LV outflow tract obstruction. Finally, diastolic dys-
function is determined with deceleration time of LV
inflow, occult systolic dysfunction detected with tissue
Doppler analysis. We did not use tissue Doppler ima-
ging in our study.
Nistri s et al. reported that body mass index and the
ratio of early diastolic peak LV inflow velocity to peak
myocardial early diastolic velocity (E/e’) ratio affect
LAV/BSA only in non-athletes. Many factors may influ-
ence LA volume [17].
Conclusion
LAV indices are sensitive markers for detecting the risk
of MACCE in patients with HCM who show normal
pump function.
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